Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2018-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于2017年度内部控制的自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2017年度内部控制的自我评价报告" which translates to "2017 Annual Internal Control Self-Evaluation Report." It discusses the company's internal control system, governance, risk management, financial management, audit, and compliance with regulatory requirements. The content is detailed and comprehensive, covering the internal control framework, implementation, supervision, and evaluation for the fiscal year 2017. It is not a full annual report (10-K) but a specific internal control self-assessment report, which aligns with the category of Audit Report / Information (AR). The document is over 8,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is a certification letter or a simple announcement. Therefore, the best fit is AR (Audit Report / Information). FY 2017
2018-04-25 Chinese
国金证券股份有限公司关于公司变更部分2012年度非公开发行股票募集资金投资项目的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Guojin Securities Co., Ltd. regarding the change in part of the 2012 non-public issuance of shares fundraising investment projects by Ruikang Pharmaceutical Co., Ltd. It discusses the original fundraising projects, the reasons for changes, new projects, market prospects, risk warnings, approval procedures, and the sponsor's opinion. The document references regulatory approvals, fundraising amounts, investment progress, and board and supervisory committee meetings approving the changes. It is not a full annual or interim financial report, nor an earnings release or call transcript. It is a regulatory compliance and verification report related to fundraising project changes, which fits best under Regulatory Filings (RNS) as it does not constitute a full financial report or a simple announcement but a compliance verification document related to fundraising use. The document length is under 5,000 characters, but it contains substantive content and detailed analysis, so it is not a mere announcement or certification. Therefore, the best classification is Regulatory Filings (RNS).
2018-04-25 Chinese
国金证券股份有限公司关于公司2017年度保荐工作报告
Regulatory Filings Classification · 90% confidence The document is titled '2017 年度保荐工作报告' which translates to '2017 Annual Sponsorship Work Report' by Guojin Securities Co., Ltd. regarding Ruikang Pharmaceutical Co., Ltd. It details the sponsorship work overview, including information disclosure review, supervision of company governance, fundraising supervision, and internal control systems. It also discusses issues found and measures taken, shareholder commitments, and other related matters. The document is a detailed report on the sponsorship activities and compliance monitoring for the year 2017, not a general annual report or financial statement. It is not an announcement or a brief summary but a substantive report on sponsorship work. This type of document aligns with the category of Regulatory Filings (RNS) as it is a regulatory compliance report related to sponsorship work rather than a financial report or management report. The document length is 4181 characters, which is relatively short but contains detailed content rather than just an announcement or certification. Therefore, the best fit is Regulatory Filings (RNS).
2018-04-25 Chinese
第三届董事会第十二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 12th meeting of the 3rd Board of Directors of 瑞康医药股份有限公司. It includes approvals of the 2017 Annual Report and its summary, the 2017 General Manager's Work Report, the 2017 Board Work Report, the 2017 Financial Statements and 2018 Budget, internal control reports, profit distribution plans, auditor reappointment, amendments to the company charter, guarantees for subsidiaries, changes in fundraising projects, financial support from controlling shareholders, and the 2018 Q1 report. The document also mentions that these reports and opinions are published on the official disclosure website (巨潮资讯网). The document is not the reports themselves but the board meeting resolutions approving these reports and proposals, which will be submitted to the shareholders' meeting for approval. The document length is 5521 characters, which is substantial but the content is clearly a board meeting resolution announcement rather than the full annual report or quarterly report. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board decisions and management reports approvals rather than containing the full reports or financial statements themselves.
2018-04-25 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to internal audit operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is issued by the company's board of directors and dated April 26, 2018. It does not contain financial statements or financial performance data, nor is it an announcement or presentation. It is a regulatory compliance or internal control self-assessment document. Given the nature of the content and the absence of financial data or report publication language, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-04-25 Chinese
2017年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled '2017年度监事会工作报告' which translates to '2017 Supervisory Board Work Report' of 瑞康医药股份有限公司. It details the supervisory board's activities, including oversight of financial statements, internal controls, compliance with laws, and company operations during the 2017 fiscal year. The report includes references to audit opinions and internal control evaluations but is not itself an audit report or annual report. It is a management-related report focusing on supervisory board work and oversight rather than full financial statements or earnings. The document length is 2366 characters, indicating a concise report rather than a full annual report. This fits best under Management Reports (MDA), which cover management's detailed explanation of financial results, business trends, and outlook, including supervisory board activities and oversight.
2018-04-25 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.